{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:10:01Z","timestamp":1790622601381,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion body myositis (IBM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed our electronic medical records to identify patients with IBM according to European Neuromuscular Center (ENMC) 2011 criteria, seen between 2015 and 2020. We only included patients who had a muscle biopsy and needle electromyography (EMG) performed on the same muscle (opposite or same side). We used a detailed grading system [0 (normal) to 4 (severe)] to score histopathological and EMG findings. Clinical severity was assessed by the modified Rankin scale (mRS), muscle strength sum score (SSS), quadriceps strength and severity of dysphagia on swallow evaluation. Serum markers of interest were creatine kinase level and cN-1A antibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 50 IBM patients, with a median age of 69\u2009years; 64% were males. Median disease duration at diagnosis was 51\u2009months. On muscle biopsy, endomysial inflammation mainly correlated with dysphagia, and inversely correlated with mRS. Vacuoles and congophilic inclusions did not correlate with any of the clinical measures. On EMG, the shortness of motor un it potential (MUP) duration correlated with all clinical measures. Myotonic discharges, and not fibrillation potentials, correlated with the severity of inflammation. Serum markers did not have a statistically significant correlation with any of the clinical measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dysphagia was the main clinical feature of IBM correlating with endomysial inflammation. Otherwise, inclusion body myositis clinical measures had limited correlation with histopathological features in this study. The shortness of MUP duration correlated with all clinical measures.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab754","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T12:17:20Z","timestamp":1633609040000},"page":"2504-2511","source":"Crossref","is-referenced-by-count":22,"title":["Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-6657","authenticated-orcid":false,"given":"Marcus V","family":"Pinto","sequence":"first","affiliation":[{"name":"Department of Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruple S","family":"Laughlin","sequence":"additional","affiliation":[{"name":"Department of Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-1236","authenticated-orcid":false,"given":"Elie","family":"Naddaf","sequence":"additional","affiliation":[{"name":"Department of Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"2022060107563093300_keab754-B1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"key":"2022060107563093300_keab754-B2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ana.410160207","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis","volume":"16","author":"Engel","year":"1984","journal-title":"Ann Neurol"},{"key":"2022060107563093300_keab754-B3","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/brain\/123.10.2030","article-title":"Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies","volume":"123","author":"Amemiya","year":"2000","journal-title":"Brain"},{"key":"2022060107563093300_keab754-B4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000265398.77681.09","article-title":"T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis","volume":"69","author":"Salajegheh","year":"2007","journal-title":"Neurology"},{"key":"2022060107563093300_keab754-B5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jns.2008.12.024","article-title":"CCR7+ myeloid dendritic cells together with CCR7+ T cells and CCR7+ macrophages invade CCL19+ nonnecrotic muscle fibers in inclusion body myositis","volume":"279","author":"Tateyama","year":"2009","journal-title":"J Neurol Sci"},{"key":"2022060107563093300_keab754-B6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.nmd.2009.07.015","article-title":"Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype","volume":"19","author":"Mastaglia","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"2022060107563093300_keab754-B7","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain"},{"key":"2022060107563093300_keab754-B8","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"key":"2022060107563093300_keab754-B9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mus.21386","article-title":"Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis","volume":"40","author":"Salajegheh","year":"2009","journal-title":"Muscle Nerve"},{"key":"2022060107563093300_keab754-B10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0140-6736(92)90388-J","article-title":"beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis","volume":"339","author":"Askanas","year":"1992","journal-title":"Lancet"},{"key":"2022060107563093300_keab754-B11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archneur.1991.00530240033013","article-title":"Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments","volume":"48","author":"Mendell","year":"1991","journal-title":"Arch Neurol"},{"key":"2022060107563093300_keab754-B12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/BOR.0b013e3282efdc7c","article-title":"Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis","volume":"19","author":"Askanas","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"2022060107563093300_keab754-B13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","article-title":"Inclusion body myositis: clinical features and pathogenesis","volume":"15","author":"Greenberg","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2022060107563093300_keab754-B14","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"2022060107563093300_keab754-B15","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.clinph.2015.12.011","article-title":"Sporadic inclusion body myositis: a review of recent clinical advances and current approaches to diagnosis and treatment","volume":"127","author":"Needham","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"2022060107563093300_keab754-B16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"2022060107563093300_keab754-B17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mus.23895","article-title":"Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia","volume":"48","author":"Pars","year":"2013","journal-title":"Muscle Nerve"},{"key":"2022060107563093300_keab754-B18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"key":"2022060107563093300_keab754-B19","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI","volume":"63(Suppl 11","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022060107563093300_keab754-B20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/mus.22321","article-title":"Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis","volume":"45","author":"Lowes","year":"2012","journal-title":"Muscle Nerve"},{"key":"2022060107563093300_keab754-B21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","article-title":"Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials","volume":"23","author":"Cortese","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"2022060107563093300_keab754-B22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.nmd.2012.05.004","article-title":"Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis","volume":"22","author":"Allenbach","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"2022060107563093300_keab754-B23","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022060107563093300_keab754-B24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/nan.12149","article-title":"Mitochondrial and inflammatory changes in sporadic inclusion body myositis","volume":"41","author":"Rygiel","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2022060107563093300_keab754-B25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5'-Nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2022060107563093300_keab754-B26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","article-title":"Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement","volume":"87","author":"Goyal","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022060107563093300_keab754-B27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"2022060107563093300_keab754-B28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann Neurol"},{"key":"2022060107563093300_keab754-B29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"2022060107563093300_keab754-B30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/mus.27157","article-title":"Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis","volume":"63","author":"Paul","year":"2021","journal-title":"Muscle Nerve"},{"key":"2022060107563093300_keab754-B31","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC International Workshop: inclusion body myositis, 2\u20134 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"2022060107563093300_keab754-B32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"van Swieten","year":"1988","journal-title":"Stroke"},{"key":"2022060107563093300_keab754-B33"},{"key":"2022060107563093300_keab754-B34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3389\/fneur.2018.00839","article-title":"Muscle biopsy and electromyography correlation","volume":"9","author":"Naddaf","year":"2018","journal-title":"Front Neurol"},{"key":"2022060107563093300_keab754-B35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2022060107563093300_keab754-B36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.55.2.296","article-title":"Disease progression in sporadic inclusion body myositis: observations in 78 patients","volume":"55","author":"Peng","year":"2000","journal-title":"Neurology"},{"key":"2022060107563093300_keab754-B37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nmd.2004.09.006","article-title":"Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies","volume":"15","author":"Teixeira","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"2022060107563093300_keab754-B38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","article-title":"Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome","volume":"87","author":"Oh","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"key":"2022060107563093300_keab754-B39","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1212\/01.WNL.0000145834.17020.86","article-title":"Primary respiratory failure in inclusion body myositis","volume":"63","author":"Voermans","year":"2004","journal-title":"Neurology"},{"key":"2022060107563093300_keab754-B40","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1212\/WNL.43.6.1241","article-title":"Inclusion body myositis presenting solely as dysphagia","volume":"43","author":"Riminton","year":"1993","journal-title":"Neurology"},{"key":"2022060107563093300_keab754-B41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mus.26996","article-title":"Myopathies featuring early or prominent dysphagia","volume":"62","author":"Triplett","year":"2020","journal-title":"Muscle Nerve"},{"key":"2022060107563093300_keab754-B42","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jnnp-2020-325141","article-title":"Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis","volume":"92","author":"Sangha","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022060107563093300_keab754-B43","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"2022060107563093300_keab754-B44","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s13311-018-0658-8","article-title":"Inclusion body myositis: update on pathogenesis and treatment","volume":"15","author":"Naddaf","year":"2018","journal-title":"Neurotherapeutics"},{"key":"2022060107563093300_keab754-B45","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11517-019-02115-6","article-title":"A new method for measurement of motor unit action potential duration based on correlation, a pilot study","volume":"58","author":"Rodr\u00edguez Carre\u00f1o","year":"2020","journal-title":"Med Biol Eng Comput"},{"key":"2022060107563093300_keab754-B46","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.clinph.2010.03.028","article-title":"Application of a novel automatic duration method measurement based on the wavelet transform on pathological motor unit action potentials","volume":"121","author":"Rodr\u00edguez-Carre\u00f1o","year":"2010","journal-title":"Clin Neurophysiol"},{"key":"2022060107563093300_keab754-B47","doi-asserted-by":"crossref","first-page":"fcaa191","DOI":"10.1093\/braincomms\/fcaa191","article-title":"Diagnostic modelling and therapeutic monitoring of immune-mediated necrotizing myopathy: role of electrical myotonia","volume":"2","author":"Triplett","year":"2020","journal-title":"Brain Commun"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab754\/40832690\/keab754.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2504\/43891811\/keab754.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2504\/43891811\/keab754.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:59:21Z","timestamp":1654070361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/6\/2504\/6383154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,7]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab754","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,10,7]]}}}